Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
India
· Delayed Price · Currency is INR 1,968.20
-5.60 (-0.28%)
At close: Dec 5, 2025
Glenmark Pharmaceuticals Revenue
Glenmark Pharmaceuticals had revenue of 60.47B INR in the quarter ending September 30, 2025, with 76.10% growth. This brings the company's revenue in the last twelve months to 159.97B, up 22.30% year-over-year. In the fiscal year ending March 31, 2025, Glenmark Pharmaceuticals had annual revenue of 133.63B with 5.68% growth.
Revenue (ttm)
159.97B
Revenue Growth
+22.30%
P/S Ratio
3.47
Revenue / Employee
10.12M
Employees
15,800
Market Cap
555.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 133.63B | 7.18B | 5.68% |
| Mar 31, 2024 | 126.45B | 9.90B | 8.49% |
| Mar 31, 2023 | 116.56B | -6.49B | -5.28% |
| Mar 31, 2022 | 123.05B | 13.61B | 12.44% |
| Mar 31, 2021 | 109.44B | 2.87B | 2.69% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Divi's Laboratories | 100.29B |
| Cipla | 279.66B |
| Apollo Hospitals Enterprise | 232.65B |
| Zydus Lifesciences | 244.94B |
| Mankind Pharma | 135.46B |
| Aurobindo Pharma | 325.14B |
| Fortis Healthcare | 84.37B |
Glenmark Pharmaceuticals News
- 5 days ago - Glenmark’s Aurangabad Facility Clears US FDA Inspection With Zero Observations - Business Upturn
- 9 days ago - Glenmark Pharma receives US FDA EIR with VAI status for Monroe facility - Business Upturn
- 11 days ago - Glenmark Pharma launches world’s first bebulized triple therapy for COPD in India - Business Upturn
- 17 days ago - HSBC cuts Glenmark’s target price to Rs 2,110, says abnormal quarter driven by upfront ISB payment and India disruption - Business Upturn
- 19 days ago - Why Glenmark Pharma shares are falling nearly 5% today: explained - Business Upturn
- 22 days ago - Top Q2 results today, November 14: Tata Motors PV, Oil India, Glenmark Pharma, MRF and more to announce earnings - Business Upturn
- 2 months ago - Glenmark Pharma board declares Rs 2.50 interim dividend for FY26 - Business Upturn
- 2 months ago - Glenmark Pharma shares fall over 2% after Trump announces 100% tariff on branded drugs - Business Upturn